



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

AMLODIPINE/CELECOXIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
AMLODIPINE BESYLATE/CELECOXIB	CONSENSI	44972		GPI-10 (3499870210)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of both hypertension and osteoarthritis and meet **ALL** of the following criteria?
 - The patient is 18 years of age or older
 - The patient had a trial of amlodipine AND celecoxib
 - The patient has an adherence or other challenge which requires the use of the combination product over separate agents
 - Consensi will NOT be used together with any other calcium channel blocker agents (e.g. diltiazem, felodipine, verapamil)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**

If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **AMLODIPINE/CELECOXIB (Consensi)** requires the following rule(s) be met for approval:

- A. You have both hypertension (abnormal high blood pressure) and osteoarthritis (a type of arthritis that occurs when tissue at the ends of your bones wears down)
- B. You are 18 years of age or older
- C. You have previously tried amlodipine AND celecoxib
- D. You have an adherence or other challenge requiring the use of the combination product over separate agents
- E. You will NOT use Consensi together with any other calcium channel blocker agents (such as diltiazem, felodipine, verapamil)

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

AMLODIPINE/CELECOXIB

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Consensi.

REFERENCES

- Consensi [Prescribing Information]. Hot Springs, AR: Burke Therapeutics, LLC; February 2017.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/20

Created: 02/20

Client Approval: 02/20

P&T Approval: 01/20